Romosozumab in Postmenopausal Women with Low Bone Mineral Density
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Sclerostin is an osteocyte-derived inhibitor of osteoblast activity. The monoclonal antibody romosozumab binds to sclerostin and increases bone formation. METHODS: In a phase 2, multicenter, international, randomized, placebo-controlled, parallel-group, eight-group study, we evaluated the efficacy and safety of romosozumab over a 12-month period in 419 postmenopausal women, 55 to 85 years of age, who had low bone mineral density (a T score of -2.0 or less at the lumbar spine, total hip, or femoral neck and -3.5 or more at each of the three sites). Participants were randomly assigned to receive subcutaneous romosozumab monthly (at a dose of 70 mg, 140 mg, or 210 mg) or every 3 months (140 mg or 210 mg), subcutaneous placebo, or an open-label active comparator--oral alendronate (70 mg weekly) or subcutaneous teriparatide (20 μg daily). The primary end point was the percentage change from baseline in bone mineral density at the lumbar spine at 12 months. Secondary end points included percentage changes in bone mineral density at other sites and in markers of bone turnover. RESULTS: All dose levels of romosozumab were associated with significant increases in bone mineral density at the lumbar spine, including an increase of 11.3% with the 210-mg monthly dose, as compared with a decrease of 0.1% with placebo and increases of 4.1% with alendronate and 7.1% with teriparatide. Romosozumab was also associated with large increases in bone mineral density at the total hip and femoral neck, as well as transitory increases in bone-formation markers and sustained decreases in a bone-resorption marker. Except for mild, generally nonrecurring injection-site reactions with romosozumab, adverse events were similar among groups. CONCLUSIONS: In postmenopausal women with low bone mass, romosozumab was associated with increased bone mineral density and bone formation and with decreased bone resorption. (Funded by Amgen and UCB Pharma; ClinicalTrials.gov number, NCT00896532.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, the simultaneous, acute increase in P1NP and reduction in CTx that we observed in the T3 group is qualitatively identical (but smaller in magnitude) to the effects of sclerostin inhibition on bone markers in humans22, and arguably pathognomonic of the consequences of sclerostin inhibition on bone.”
From Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial (2024) · cites this paper as [22]
In the citing paper
“the time course of changes in bone formation we observed over 20 weeks of intermittent D + Q treatment in the T3 group is virtually identical (albeit smaller in magnitude) to that observed following treatment with the FDA-approved sclerostin inhibitor, romosozumab, where serum P1NP increased rapidly over the first 1–4 weeks following dosing and then returned to baseline by 24 weeks22.”
From Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial (2024) · cites this paper as [22]
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Osteoporosis Prevention, Diagnosis, and Therapy
NIH Consensus Development Panel on Osteoporosis Prevention, D. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.6.785 · Cited by 5,529
WNT signaling in bone homeostasis and disease: From human mutations to treatments
Baron, R., & Kneissel, M. (2013) · Nature Medicine · doi:10.1038/nm.3074 · Cited by 2,093
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation
Poole, K. E. S., Van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Löwik, C. W., & Reeve, J. (2005) · The FASEB Journal · doi:10.1096/fj.05-4221fje · Cited by 965
Li, X., Ominsky, M. S., Niu, Q.-T., Sun, N., Daugherty, B., D'Agostin, D., Kurahara, C., Gao, Y., Cao, J., Gong, J., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080216 · Cited by 936
Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody
Padhi, D., Jang, G., Stouch, B., Fang, L., & Posvar, E. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.173 · Cited by 786
Li, X., Ominsky, M. S., Warmington, K. S., Morony, S., Gong, J., Cao, J., Gao, Y., Shalhoub, V., Tipton, B., Haldankar, R., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081206 · Cited by 784
Targeting the Wnt/β-Catenin Pathway to Regulate Bone Formation in the Adult Skeleton
Baron, R., & Rawadi, G. (2007) · Endocrinology · doi:10.1210/en.2007-0270 · Cited by 584
Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease
Loots, G. G., Kneissel, M., Keller, H., Baptist, M., Chang, J., Collette, N. M., Ovcharenko, D., Plajzer-Frick, I., & Rubin, E. M. (2005) · Genome Research · doi:10.1101/gr.3437105 · Cited by 442
Cited by
Compston, J. E., McClung, M. R., & Leslie, W. D. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32112-3 · Cited by 2,449
Self-citationFracture healing: mechanisms and interventions
Einhorn, T. A., & Gerstenfeld, L. C. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.164 · Cited by 1,807
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
Cosman, F., Crittenden, D. B., Adachi, J. D., Binkley, N., Czerwinski, E., Ferrari, S., Hofbauer, L. C., Lau, E., Lewiecki, E. M., Miyauchi, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607948 · Cited by 1,805
Self-citationRomosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
Saag, K. G., Petersen, J., Brandi, M. L., Karaplis, A. C., Lorentzon, M., Thomas, T., Maddox, J., Fan, M., Meisner, P. D., & Grauer, A. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708322 · Cited by 1,544
Self-citationOsteoporosis treatment: recent developments and ongoing challenges
Khosla, S., & Hofbauer, L. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30188-2 · Cited by 1,019
Eastell, R., O'Neill, T. W., Hofbauer, L. C., Langdahl, B., Reid, I. R., Gold, D. T., & Cummings, S. R. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.69 · Cited by 827
Self-citationDrug therapy for osteoporosis in older adults
Reid, I. R., & Billington, E. O. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02646-5 · Cited by 698
Kenkre, J., & Bassett, J. (2018) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563218759371 · Cited by 693
Use of bone turnover markers in postmenopausal osteoporosis
Eastell, R., & Szulc, P. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30184-5 · Cited by 594
Parathyroid hormone: anabolic and catabolic actions on the skeleton
Silva, B. C., & Bilezikian, J. P. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.03.005 · Cited by 557
Langdahl, B. L., Libanati, C., Crittenden, D. B., Bolognese, M. A., Brown, J. P., Daizadeh, N. S., Dokoupilova, E., Engelke, K., Finkelstein, J. S., Genant, H. K., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31613-6 · Cited by 497
Self-citationDrug development in the era of precision medicine
Dugger, S. A., Platt, A., & Goldstein, D. B. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.226 · Cited by 493
Advances in pathogenesis and therapeutic strategies for osteoporosis
Song, S., Guo, Y., Yang, Y., & Fu, D. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108168 · Cited by 476
Self-citationShoback, D., Rosen, C. J., Black, D. M., Cheung, A. M., Murad, M. H., & Eastell, R. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa048 · Cited by 439
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Role and mechanism of action of sclerostin in bone
Delgado-Calle, J., Sato, A. Y., & Bellido, T. (2017) · Bone · doi:10.1016/j.bone.2016.10.007 · Cited by 443
Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis
Langdahl, B., Ferrari, S., & Dempster, D. W. (2016) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x16670154 · Cited by 432
Self-citationWNT–β-catenin signalling — a versatile player in kidney injury and repair
Schunk, S. J., Floege, J., Fliser, D., & Speer, T. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00343-w · Cited by 427
Walker, M. D., & Shane, E. (2023) · New England Journal of Medicine · doi:10.1056/nejmcp2307353 · Cited by 381
Osteoclasts: more than ‘bone eaters’
Charles, J. F., & Aliprantis, A. O. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.06.001 · Cited by 391
Bone Turnover Markers in the Diagnosis and Monitoring of Metabolic Bone Disease
Greenblatt, M. B., Tsai, J. N., & Wein, M. N. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2016.259085 · Cited by 376
The role of the wnt/β-catenin signaling pathway in formation and maintenance of bone and teeth
Duan, P., & Bonewald, L. F. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.05.015 · Cited by 375
Wnt/β-catenin signaling components and mechanisms in bone formation, homeostasis, and disease
Hu, L., Chen, W., Qian, A., & Li, Y.-P. (2024) · Bone Research · doi:10.1038/s41413-024-00342-8 · Cited by 359
Lewiecki, E. M., Blicharski, T., Goemaere, S., Lippuner, K., Meisner, P. D., Miller, P. D., Miyauchi, A., Maddox, J., Chen, L., & Horlait, S. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02163 · Cited by 328
Self-citationRecker, R. R., Benson, C. T., Matsumoto, T., Bolognese, M. A., Robins, D. A., Alam, J., Chiang, A. Y., Hu, L., Krege, J. H., Sowa, H., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2351 · Cited by 293
Self-citationThe role of osteoblasts in energy homeostasis
Dirckx, N., Moorer, M. C., Clemens, T. L., & Riddle, R. C. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0246-y · Cited by 292
The Pathophysiology and Treatment of Osteoporosis
Drake, M. T., Clarke, B. L., & Lewiecki, E. M. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.06.006 · Cited by 290
A look behind the scenes: the risk and pathogenesis of primary osteoporosis
Hendrickx, G., Boudin, E., & Van Hul, W. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.48 · Cited by 285
Skeletal Aging and Osteoporosis: Mechanisms and Therapeutics
Chandra, A., & Rajawat, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073553 · Cited by 264
Functional Biomaterials for Bone Regeneration: A Lesson in Complex Biology
Armiento, A. R., Hatt, L. P., Sanchez Rosenberg, G., Thompson, K., & Stoddart, M. J. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201909874 · Cited by 273
Farr, J. N., & Khosla, S. (2019) · Bone · doi:10.1016/j.bone.2019.01.015 · Cited by 263
A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair
Florio, M., Gunasekaran, K., Stolina, M., Li, X., Liu, L., Tipton, B., Salimi-Moosavi, H., Asuncion, F. J., Li, C., Sun, B., et al. (2016) · Nature Communications · doi:10.1038/ncomms11505 · Cited by 257
Crandall, C. J., Newberry, S. J., Diamant, A., Lim, Y.-W., Gellad, W. F., Booth, M. J., Motala, A., & Shekelle, P. G. (2014) · Annals of Internal Medicine · doi:10.7326/m14-0317 · Cited by 254
The WNT system: background and its role in bone
Lerner, U. H., & Ohlsson, C. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12368 · Cited by 228
Physiological and pathophysiological bone turnover — role of the immune system
Weitzmann, M. N., & Ofotokun, I. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.91 · Cited by 240
McClung, M. R., Brown, J. P., Diez-Perez, A., Resch, H., Caminis, J., Meisner, P., Bolognese, M. A., Goemaere, S., Bone, H. G., Zanchetta, J. R., et al. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3452 · Cited by 240
Self-citationUpdate on Osteoporosis Screening and Management
Anam, A. K., & Insogna, K. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.05.016 · Cited by 232
Händel, M. N., Cardoso, I., von Bülow, C., Rohde, J. F., Ussing, A., Nielsen, S. M., Christensen, R., Body, J.-J., Brandi, M. L., Diez-Perez, A., et al. (2023) · BMJ · doi:10.1136/bmj-2021-068033 · Cited by 219
Self-citationOverview of treatment approaches to osteoporosis
Langdahl, B. L. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15024 · Cited by 207
Self-citationEvenepoel, P., Cunningham, J., Ferrari, S., Haarhaus, M., Javaid, M. K., Lafage-Proust, M.-H., Prieto-Alhambra, D., Torres, P. U., Cannata-Andia, J., European Renal Osteodystrophy (EUROD) workgroup, A. I. O. T. C.-M. W. G. O. T. E.-E., et al. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa192 · Cited by 207
Wnt Signaling in vascular eye diseases
Wang, Z., Liu, C.-H., Huang, S., & Chen, J. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.11.008 · Cited by 211
Molecular genetics and targeted therapy of WNT-related human diseases (Review)
Katoh, M., & Katoh, M. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3071 · Cited by 207
Lewiecki, E. M., Dinavahi, R. V., Lazaretti-Castro, M., Ebeling, P. R., Adachi, J. D., Miyauchi, A., Gielen, E., Milmont, C. E., Libanati, C., & Grauer, A. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3622 · Cited by 207
Self-citationOsteocytic signalling pathways as therapeutic targets for bone fragility
Plotkin, L. I., & Bellido, T. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.71 · Cited by 206
Osteocytes: The master cells in bone remodelling
Prideaux, M., Findlay, D. M., & Atkins, G. J. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.02.003 · Cited by 210
Treating osteoporosis to prevent fractures: current concepts and future developments
Lorentzon, M. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12873 · Cited by 203
Black, D. M., Abrahamsen, B., Bouxsein, M. L., Einhorn, T., & Napoli, N. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00001 · Cited by 198
Short-term and long-term effects of osteoporosis therapies
Reid, I. R. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.71 · Cited by 201
Fracture healing physiology and the quest for therapies for delayed healing and nonunion
Kostenuik, P., & Mirza, F. M. (2017) · Journal of Orthopaedic Research · doi:10.1002/jor.23460 · Cited by 184
Cell Biology of Canonical Wnt Signaling
Albrecht, L. V., Tejeda-Muñoz, N., & De Robertis, E. M. (2021) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-120319-023657 · Cited by 187
McDonald, M. M., Reagan, M. R., Youlten, S. E., Mohanty, S. T., Seckinger, A., Terry, R. L., Pettitt, J. A., Simic, M. K., Cheng, T. L., Morse, A., et al. (2017) · Blood · doi:10.1182/blood-2017-03-773341 · Cited by 185
The osteocyte: A multifunctional cell within the bone
Tresguerres, F. G. F., Torres, J., López-Quiles, J., Hernández, G., Vega, J. A., & Tresguerres, I. F. (2020) · Annals of Anatomy - Anatomischer Anzeiger · doi:10.1016/j.aanat.2019.151422 · Cited by 179
Migliorini, F., Maffulli, N., Colarossi, G., Eschweiler, J., Tingart, M., & Betsch, M. (2021) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-021-02678-x · Cited by 182
Sclerostin influences body composition by regulating catabolic and anabolic metabolism in adipocytes
Kim, S. P., Frey, J. L., Li, Z., Kushwaha, P., Zoch, M. L., Tomlinson, R. E., Da, H., Aja, S., Noh, H. L., Kim, J. K., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707876115 · Cited by 176
Chavassieux, P., Chapurlat, R., Portero-Muzy, N., Roux, J.-P., Garcia, P., Brown, J. P., Libanati, C., Boyce, R. W., Wang, A., & Grauer, A. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3735 · Cited by 176
Self-citationDegeneration of the osteocyte network in the C57BL/6 mouse model of aging
Tiede-Lewis, L. M., Xie, Y., Hulbert, M. A., Campos, R., Dallas, M. R., Dusevich, V., Bonewald, L. F., & Dallas, S. L. (2017) · Aging · doi:10.18632/aging.101308 · Cited by 176
Cosman, F., Crittenden, D. B., Ferrari, S., Khan, A., Lane, N. E., Lippuner, K., Matsumoto, T., Milmont, C. E., Libanati, C., & Grauer, A. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3427 · Cited by 175
Self-citationUluçkan, Ö., Jimenez, M., Karbach, S., Jeschke, A., Graña, O., Keller, J., Busse, B., Croxford, A. L., Finzel, S., Koenders, M., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad8996 · Cited by 170
Disuse Osteoporosis: Clinical and Mechanistic Insights
Rolvien, T., & Amling, M. (2022) · Calcified Tissue International · doi:10.1007/s00223-021-00836-1 · Cited by 162
Davis, S., Simpson, E., Hamilton, J., James, M. M.-S., Rawdin, A., Wong, R., Goka, E., Gittoes, N., & Selby, P. (2020) · Health Technology Assessment · doi:10.3310/hta24290 · Cited by 164
New horizons in treatment of osteoporosis
Tabatabaei-Malazy, O., Salari, P., Khashayar, P., & Larijani, B. (2017) · DARU Journal of Pharmaceutical Sciences · doi:10.1186/s40199-017-0167-z · Cited by 166
Postmenopausal osteoporosis coexisting with sarcopenia: the role and mechanisms of estrogen
Lu, L., & Tian, L. (2023) · Journal of Endocrinology · doi:10.1530/joe-23-0116 · Cited by 192
Osteoporosis in patients with chronic kidney diseases: A systemic review
Hsu, C.-Y., Chen, L.-R., & Chen, K.-H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186846 · Cited by 162
SIKs control osteocyte responses to parathyroid hormone
Wein, M. N., Liang, Y., Goransson, O., Sundberg, T. B., Wang, J., Williams, E. A., O’Meara, M. J., Govea, N., Beqo, B., Nishimori, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms13176 · Cited by 163
The Osteoclast in Bone Metastasis: Player and Target
Maurizi, A., & Rucci, N. (2018) · Cancers · doi:10.3390/cancers10070218 · Cited by 160
HDAC5 Controls MEF2C-Driven Sclerostin Expression in Osteocytes
Wein, M. N., Spatz, J., Nishimori, S., Doench, J., Root, D., Babij, P., Nagano, K., Baron, R., Brooks, D., Bouxsein, M., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2381 · Cited by 158
Bone Health and Osteoporosis Prevention and Treatment
MUÑOZ, M., ROBINSON, K., & Shibli-Rahhal, A. A. (2020) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000572 · Cited by 165
Reichert, J. M. (2014) · mAbs · doi:10.4161/19420862.2015.988944 · Cited by 156
Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders
Vervloet, M. G., Massy, Z. A., Brandenburg, V. M., Mazzaferro, S., Cozzolino, M. G., Ureña, P., Bover, J., & Goldsmith, D. J. A. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70059-2 · Cited by 167
Carrillo‐López, N., Panizo, S., Alonso‐Montes, C., Román‐García, P., Rodríguez, I., Martínez‐Salgado, C., Dusso, A., Naves‐Díaz, M., & Cannata-Andía, J. B. (2016) · Kidney International · doi:10.1016/j.kint.2016.01.024 · Cited by 163
Glorieux, F. H., Devogelaer, J., Durigova, M., Goemaere, S., Hemsley, S., Jakob, F. J., JUNKER, U., Ruckle, J., Seefried, L., & Winkle, P. J. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3143 · Cited by 153
Side effects of drugs for osteoporosis and metastatic bone disease
Skjødt, M. K., Frost, M., & Abrahamsen, B. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13759 · Cited by 171
Lassen, N. E., Andersen, T. L., Pløen, G. G., Søe, K., Hauge, E. M., Harving, S., Eschen, G. E. T., & Delaisse, J.-M. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3091 · Cited by 152
Muscle-bone interactions: From experimental models to the clinic? A critical update
Laurent, M. R., Dubois, V., Claessens, F., Verschueren, S., Vanderschueren, D., Gielen, E., & Jardí, F. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.10.017 · Cited by 163
Bergen, D. J. M., Kague, É., & Hammond, C. L. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00006 · Cited by 166
Sclerostin and DKK1: new players in renal bone and vascular disease
Evenepoel, P., D’Haese, P. C., & Brandenburg, V. M. (2015) · Kidney International · doi:10.1038/ki.2015.156 · Cited by 154
Vico, L., van Rietbergen, B., Vilayphiou, N., Linossier, M., Locrelle, H., Normand, M., Zouch, M., Gerbaix, M., Bonnet, N., Novikov, V., et al. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3188 · Cited by 170
The Bone Marrow-Derived Stromal Cells: Commitment and Regulation of Adipogenesis
Tencerova, M., & Kassem, M. (2016) · Frontiers in Endocrinology · doi:10.3389/fendo.2016.00127 · Cited by 149
Pharmacological Management of Postmenopausal Osteoporosis: a Level I Evidence Based - Expert Opinion
Migliorini, F., Colarossi, G., Baroncini, A., Eschweiler, J., Tingart, M., & Maffulli, N. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1851192 · Cited by 155
Bi, H., Chen, X., Gao, S., Yu, X., Xiao, J., Zhang, B., Liu, X., & Dai, M. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00234 · Cited by 152
Cytokine-mediated immunomodulation of osteoclastogenesis
Zhou, P., Zheng, T., & Zhao, B. (2022) · Bone · doi:10.1016/j.bone.2022.116540 · Cited by 156
New developments in biological markers of bone metabolism in osteoporosis
Garnero, P. (2014) · Bone · doi:10.1016/j.bone.2014.05.016 · Cited by 148
Genant, H. K., Engelke, K., Bolognese, M. A., Mautalén, C., Brown, J. P., Recknor, C. P., Goemaere, S., Fuerst, T. P., Yang, Y., Grauer, A., et al. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2932 · Cited by 143
Self-citationThe diverse origin of bone-forming osteoblasts
Mizoguchi, T., & Ono, N. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4410 · Cited by 161
Effect of osteoporosis medications on fracture healing
Hegde, V. V., Jo, J. E., Andreopoulou, P., & Lane, J. M. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3331-7 · Cited by 144
The skeletal cell‐derived molecule sclerostin drives bone marrow adipogenesis
Fairfield, H. E., Falank, C. R., Harris, E., DeMambro, V., McDonald, M. M., Pettitt, J. A., Mohanty, S. T., Croucher, P. I., Krämer, I., Kneissel, M., et al. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25976 · Cited by 140
Bone turnover: Biology and assessment tools
Szulc, P. (2018) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2018.05.003 · Cited by 158
Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction
Wehmeyer, C., Frank, S., Beckmann, D., Böttcher, M., Cromme, C., König, U., Fennen, M., Held, A., Paruzel, P., Hartmann, C., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aac4351 · Cited by 141
Migliorini, F., Maffulli, N., Spiezia, F., Peretti, G. M., Tingart, M., & Giorgino, R. (2021) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-021-02497-0 · Cited by 141
Effects of sclerostin antibodies in animal models of osteoporosis
Ominsky, M. S., Boyce, R. W., Li, X., & Ke, H. Z. (2016) · Bone · doi:10.1016/j.bone.2016.10.019 · Cited by 140
Current use of bone turnover markers in the management of osteoporosis
Brown, J. P., Don-Wauchope, A., Douville, P., Albert, C., & Vasikaran, S. D. (2022) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2022.09.002 · Cited by 152
Self-citationQureshi, A. R., Olauson, H., Witasp, A., Haarhaus, M. L., Brandenburg, V. M., Wernerson, A. M., Lindholm, B., Söderberg, M. P., Wennberg, L. M., Nordfors, L., et al. (2015) · Kidney International · doi:10.1038/ki.2015.194 · Cited by 135
Yue, R., Shen, B., & Morrison, S. J. (2016) · eLife · doi:10.7554/elife.18782 · Cited by 139
Protective alleles and modifier variants in human health and disease
Harper, A. R., Nayee, S., & Topol, E. J. (2015) · Nature Reviews Genetics · doi:10.1038/nrg4017 · Cited by 141
Delgado‐Calle, J., Anderson, J. L., Cregor, M. D., Condon, K. W., Kuhstoss, S., Plotkin, L. I., Bellido, T., & Roodman, G. D. (2017) · Leukemia · doi:10.1038/leu.2017.152 · Cited by 134
Kendler, D. L., Bone, H. G., Massari, F., Gielen, E., Palacios, S., Maddox, J., Yan, C., Yue, S. V., Dinavahi, R. V., Libanati, C. R., et al. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05146-9 · Cited by 131
Self-citationFarr, J. N., Atkinson, E. J., Achenbach, S. J., Volkman, T. L., Tweed, A. J., Vos, S. J., Ruan, M., Sfeir, J., Drake, M. T., Saul, D., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03096-2 · Cited by 127
Management of Osteoporosis in CKD
Khairallah, P., & Nickolas, T. L. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11031017 · Cited by 136
Osteocytic oxygen sensing controls bone mass through epigenetic regulation of sclerostin
Stegen, S., Stockmans, I., Moermans, K., Thienpont, B., Maxwell, P. H., Carmeliet, P., & Carmeliet, G. (2018) · Nature Communications · doi:10.1038/s41467-018-04679-7 · Cited by 126
Sclerostin Antibody Administration Converts Bone Lining Cells Into Active Osteoblasts
Kim, S. W., Lu, Y., Williams, E. A., Lai, F., Lee, J. Y., Enishi, T., Balani, D., Ominsky, M. S., Ke, H. Z., Kronenberg, H. M., et al. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3038 · Cited by 130
Metadata
- Authors
- McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., Katz, L., Maddox, J., Yang, Y.-C., Libanati, C., & Bone, H. G.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- Amgen (United States) (US)
- KU Leuven (BE)
- National Institutes of Health (US)
- Centre hospitalier universitaire de Québec (CA)
- Aarhus University Hospital (DK)
- University of Liège (BE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-01-30
- Volume
- 370
- Issue
- 5
- Pages
- 412-420
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2096627331
- Cited by
- 1,258
- References
- 16
- Citations by year
- 2026: 75 · 2025: 97 · 2024: 82 · 2023: 52 · 2022: 99 · 2021: 93 · 2020: 121 · 2019: 69 · 2018: 90 · 2017: 105 · 2016: 125 · 2015: 139 · 2014: 101
- FWCI
- 160.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Bank (Australian Catholic University) (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- romosozumab, sclerostin, postmenopausal osteoporosis, osteopenia, bone mineral density, bone formation, bone resorption, alendronate, teriparatide, osteocytes, osteoblast activity, monoclonal antibodies, dose comparison, injection site reactions
- MeSH terms
- Aged, Aged, 80 and over, Antibodies, Monoclonal, Calcium, Drug Administration Schedule, Female, Humans, Injections, Subcutaneous, Lumbar Vertebrae, Middle Aged, Biomarkers, Bone Density, Osteoporosis, Postmenopausal, Least-Squares Analysis, Bone Remodeling, Teriparatide, Alendronate, Bone Density Conservation Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.